What do systematic reviews say?

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine probably leads to higher hypothyroidism compared with radioiodine (moderate certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 2.53 [1.52, 4.2]
  6 studies · 321 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine showed no clear difference in adverse events compared with radioiodine (low certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 1.24 [0.94, 1.63]
  6 studies · 321 participants
  Low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 268 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

The review found no eligible studies for this question.

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

It is very uncertain whether the intervention changes recurrence of hyperthyroidism (relapse) [measured by serum thyroid… (very low certainty).

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 2.66]
  2 studies · 417 participants
  Very low

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 425 participants
  GRADE not reported

Intervention not reported

The intervention may leads to higher development and worsening of Graves' ophthalmopathy [examination by… (low certainty).

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  RR 1.94 [1.4, 2.7]
  2 studies · 417 participants
  Low

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 112 participants
  GRADE not reported

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 104 participants
  Very low

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 425 participants
  GRADE not reported

Intervention not reported

• Radioiodine therapy versus antithyroid medications for Graves' disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 112 participants
  GRADE not reported